We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.

learn more


Investor Day and July Meetings Recap

Hi, I’m Alex Schwartz and I recently joined Esperion as Head of Investor Relations.  Prior to joining Esperion, I was… more

Posted by mlowe@esperion.com

A Closer Look – June 2018

As we approach the halfway point in 2018, our Lipid Management Team remains confident and encouraged by the consistently positive… more

Posted by mlowe@esperion.com

Key Insights from March 2018 ACC: CLEAR Outcomes Looking Even CLEARer After ODYSSEY – Updated ICER Cost-Effectiveness Analysis A Win for Patients and for the Bempedoic Acid Franchise

Our Lipid Management Team attended the 67th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando this… more

Posted by mlowe@esperion.com